Does leukotriene modulation of eosinophil function explain the therapeutic effectiveness of receptor antagonists in some patients with asthma?
Busse
W W
WW
D000085:Acetates / Q000037:antagonists & inhibitors*; D018927:Anti-Asthmatic Agents / Q000037:antagonists & inhibitors*; D001249:Asthma / Q000188:drug therapy*; D003521:Cyclopropanes; D004730:Endothelium, Vascular / Q000166:cytology / Q000187:drug effects; D004804:Eosinophils / Q000187:drug effects* / Q000502:physiology*; D006801:Humans; D020024:Leukotriene Antagonists / Q000627:therapeutic use*; D015289:Leukotrienes / Q000494:pharmacology*; D011804:Quinolines / Q000037:antagonists & inhibitors*; D013440:Sulfides; D016896:Treatment Outcome
D000085:Acetates; D018927:Anti-Asthmatic Agents; D003521:Cyclopropanes; D020024:Leukotriene Antagonists; D015289:Leukotrienes; D011804:Quinolines; D013440:Sulfides; C093875:montelukast